![[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.](/media/k2/items/cache/e3823fe2e02931eee83f491ba1ee32af_L.jpg)
[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.
Heparin for Moderately Ill Patients with Covid-19 – medRxiv Related: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. AND [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin […]
The post [Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- M-A | Catheter-directed thrombolysis vs. systemic thrombolysis and anticoagulation in intermediate- or high-risk pulmonary embolism
- AHA Scientific Statement | Pulmonary hypertension in congenital heart disease
- RCT | Cytisinicline shows significant efficacy in smoking cessation over placebo
- M-A | Adjunctive corticosteroids improve survival, clinical outcomes in severe community-acquired pneumonia
- M-A | Drug therapies for treatment of idiopathic pulmonary fibrosis
Laissez un commentaire
Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.